Palmer RH

Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation.

Treis D, Umapathy G, Fransson S, ..., Martinsson T, Kogner P

JCO Precision Oncology 6 (6) e2100271 [2022-01-00; online 2022-01-28]

Clinical Genomics [Service] Clinical Genomics Gothenburg [Service] Clinical Genomics Stockholm [Service]

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.

Szydzik J, Lind DE, Arefin B, ..., Hallberg B, Palmer RH

Nat Commun 12 (1) 6813 [2021-11-24; online 2021-11-24]

Glycoproteomics and MS Proteomics [Service]

Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells.

Siaw JT, Gabre JL, Uçkun E, ..., Palmer RH, Guan J

Cancers (Basel) 13 (8) - [2021-04-15; online 2021-04-15]

Glycoproteomics and MS Proteomics [Service]

ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.

Borenäs M, Umapathy G, Lai WY, ..., Hallberg B, Palmer RH

EMBO J. 40 (3) e105784 [2021-02-01; online 2021-01-07]

Clinical Genomics [Collaborative] Clinical Genomics Gothenburg [Collaborative] Glycoproteomics and MS Proteomics [Service]